Methodology
How we collect and report data
This page explains how DOZA collects internal data on client outcomes, what limitations this data has, and how it differs from randomized clinical trials (RCTs).
What we collect
Weight change
Starting weight and weight at each checkpoint (monthly). Self-reported by client.
Protocol adherence
Whether the client continues the program at 1, 3, and 6 months. Tracked automatically via order system.
Side effects
Self-reported side effects via specialist chat or survey. Categories: gastrointestinal, systemic, local.
Satisfaction
NPS and text reviews after 1 and 3 months. Collected via Google Forms and Telegram bot.
Sample sizes
Figures as of May 2026. Updated quarterly.
Limitations of our data
No control group (placebo) — impossible to assess what portion of the outcome is due to the product vs. lifestyle changes.
No randomization — clients self-select products, creating selection bias.
Self-reported data — weight is reported by the client, not measured in a standardized clinical setting.
Survivorship bias — clients who discontinued are less likely to report outcomes.
No blinding — both client and specialist know which product is being used.
No independent audit — data is collected and analyzed by DOZA, not a third party.
Bias disclosure
- DOZA is a commercial organization that sells the products whose outcomes it measures. This creates a conflict of interest.
- We publish data that may be favorable to our products and strive for transparency about this limitation.
- Our data is NOT a substitute for randomized clinical trials. For medical decisions, refer to publications in NEJM, The Lancet, Nature Medicine.
- We encourage independent verification of our data and are willing to provide anonymized datasets upon researcher request.
Comparison with RCTs
When our website cites data like "up to -22% weight loss," these are results from published RCTs, not our internal data. Key differences:
| RCT | DOZA | |
|---|---|---|
| Control group | Yes (placebo) | No |
| Randomization | Yes | No |
| Blinding | Double-blind | No |
| Measurement | Clinically standardized | Self-reported |
| Sample size | ~2,500 (SURMOUNT-1) | ~1,200 with complete data |
| Duration | 72 weeks (SURMOUNT-1) | 3-12 months |
| Publication | Peer-reviewed journal | Internal data |
Our internal data complements but does not replace published clinical trials.
How we ensure transparency
Source labeling
Each page indicates whether data is from RCTs or internal.
SourcesFooter
Every product page has a sources section with PubMed/NEJM links.
Research Policy
4-tier product classification by regulatory status.
Open data
Anonymized aggregate outcomes available at /research and /rezultaty.
Important information
This page describes DOZA's internal data collection methodology. The information is not a scientific publication and does not replace specialist consultation. For medical decisions, follow your doctor's recommendations and published clinical research.